secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-07-05T23:59:59+00:00
Accession:  0001140361-24-032511
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director resigns; Nasdaq confirms Gyre out of compliance on audit committee composition
--------------------------------------------------------------------------------

- Nassim Usman resigned from Board and Audit Committee, effective June 30, 2024, not due to any disagreements.
- On July 2, Nasdaq notified Gyre of non-compliance with Listing Rule 5605 (audit committee independence requirements).
- Cure period runs until earlier of next annual meeting or June 30, 2025; company is recruiting a new independent director.
- Company intends to reestablish compliance within cure period and avoid delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124032511/0001140361-24-032511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124032511/ef20032140_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-032511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer